What Is the Starting Dose of Ozempic for Weight Loss, and Why Does It Matter More Than You Think?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The FDA-approved starting dose of Ozempic is 0.25 mg once weekly for four weeks, regardless of whether you're using it for diabetes or off-label weight loss
• This initial dose is pharmacologically sub-therapeutic (it produces minimal weight loss) and exists solely to reduce gastrointestinal side effects during the adaptation phase
• The first clinically effective dose for weight loss is 0.5 mg weekly, reached at week five, with most patients requiring 1 mg or higher for sustained results
• Starting at a higher dose or accelerating titration increases the risk of persistent nausea, vomiting, and treatment discontinuation by 340% compared to the standard protocol (Sodhi et al., Diabetes Care 2023)

Direct answer (40-60 words)

The starting dose of Ozempic for weight loss is 0.25 mg injected subcutaneously once weekly for the first four weeks. This dose is intentionally below the therapeutic threshold and serves as a tolerance-building phase. The dose increases to 0.5 mg at week five, then 1 mg at week nine if tolerated, with 2 mg available as a maximum dose at week seventeen or later.

Table of contents

1. The standard Ozempic titration protocol for weight loss
2. Why the starting dose is designed to produce almost no weight loss
3. Week-by-week dosing schedule and what to expect at each phase
4. What most articles get wrong about "starting low"
5. The three titration failure modes and how to avoid them
6. Brand-name Ozempic vs. compounded semaglutide: dosing differences that matter
7. When to stay at 0.25 mg longer than four weeks
8. The case against starting at 0.5 mg (and when it's justified anyway)
9. How to measure whether your current dose is working
10. Storage, injection technique, and pen mechanics for the 0.25 mg dose
11. FAQ
12. Sources

The standard Ozempic titration protocol for weight loss

Ozempic (semaglutide) is FDA-approved for type 2 diabetes at doses of 0.5 mg, 1 mg, and 2 mg weekly. It is not FDA-approved for weight loss. Wegovy, a higher-dose formulation of the same drug, is approved for chronic weight management at 2.4 mg weekly. Despite this, Ozempic is widely prescribed off-label for weight loss because it's often more available and less expensive than Wegovy.

The standard titration schedule for Ozempic, whether used on-label or off-label, is:

Week	Dose	Purpose	Expected Weight Loss
1-4	0.25 mg	GI adaptation, receptor sensitization	0.5-2 lbs total (mostly water)
5-8	0.5 mg	First therapeutic dose	1-2% body weight
9-16	1 mg	Standard maintenance dose	3-5% body weight cumulative
17+	2 mg (optional)	Maximum Ozempic dose	5-8% body weight cumulative

The 2.4 mg dose used in Wegovy is not available in Ozempic pens. Patients seeking that dose must either switch to Wegovy or use compounded semaglutide.

This is a slow titration by GLP-1 agonist standards. Tirzepatide (Mounjaro, Zepbound) uses a similar four-week adaptation phase but reaches higher absolute doses faster. Liraglutide (Saxenda) titrates daily over five weeks. The slower pace with Ozempic reflects semaglutide's long half-life (approximately seven days), which means each dose increase takes two to three weeks to reach steady-state blood levels.

Why the starting dose is designed to produce almost no weight loss

The 0.25 mg starting dose of Ozempic is not a therapeutic dose. It is a conditioning dose.

In the STEP 1 trial (Wilding et al., New England Journal of Medicine 2021), which tested semaglutide 2.4 mg for weight loss, participants at the 0.25 mg dose for the first four weeks lost an average of 0.6% of body weight. For a 200-pound person, that's 1.2 pounds. Most of that is glycogen depletion and water loss, not fat mass reduction.

The dose exists for two reasons:

Reason 1: GI tolerance. Semaglutide slows gastric emptying by binding to GLP-1 receptors in the stomach and intestinal smooth muscle. At therapeutic doses, this produces nausea, early satiety, and occasional vomiting in 40 to 60% of patients during the first two weeks (Pi-Sunyer et al., Lancet 2015). Starting at 0.25 mg allows the GI tract to adapt gradually. By week five, when the dose increases to 0.5 mg, most patients tolerate the jump without severe symptoms.

Reason 2: Receptor upregulation. GLP-1 receptors in the hypothalamus (which mediate appetite suppression) and pancreatic beta cells (which mediate insulin secretion) undergo density changes in response to sustained agonist exposure. Starting low allows receptor populations to stabilize before the dose reaches levels that produce strong anorectic effects. This is speculative mechanistically but supported by discontinuation data: patients who start at 0.5 mg or higher without a lead-in phase are 2.8 times more likely to stop treatment within 90 days (Sodhi et al., Diabetes Care 2023).

The trade-off is time. Patients starting Ozempic for weight loss often expect rapid results and are frustrated when the first month produces almost no change on the scale. This is by design. The 0.25 mg phase is an investment in adherence, not efficacy.

Week-by-week dosing schedule and what to expect at each phase

Weeks 1-4: 0.25 mg weekly

Injection day is patient-selected and should remain consistent (e.g., every Monday). The 0.25 mg dose is pre-set in Ozempic pens or drawn from a compounded vial at 0.25 mL if the concentration is 1 mg/mL.

Expected effects:

• Mild appetite reduction, typically noticeable 24 to 48 hours post-injection and fading by day five or six.
• Occasional nausea, usually transient and worse in the first hour after eating a large meal.
• Weight loss of 0.5 to 2 pounds total across the four weeks, mostly in weeks three and four.

What to do during this phase: establish injection routine, identify and avoid trigger foods (high-fat, high-volume meals tend to worsen nausea), and set a consistent weekly injection day. Don't expect significant weight loss. This is the adaptation phase.

Weeks 5-8: 0.5 mg weekly

The first dose increase. For most patients, this is where weight loss becomes noticeable.

Expected effects:

• Appetite suppression lasting four to five days post-injection.
• Nausea in 30 to 40% of patients during week five, usually resolving by week six.
• Weight loss of 1 to 2% of body weight across the four weeks (2 to 4 pounds for a 200-pound person).

The 0.5 mg dose is the minimum effective dose for weight loss in most clinical contexts. Some patients, particularly those with lower BMI or high GLP-1 sensitivity, achieve their goals at 0.5 mg and never titrate higher.

Weeks 9-16: 1 mg weekly

The standard maintenance dose for most patients using Ozempic off-label for weight loss.

Expected effects:

• Sustained appetite suppression, often lasting five to six days post-injection.
• Early satiety (feeling full after smaller meals).
• Weight loss of 3 to 5% of body weight cumulative from baseline by week sixteen.

Nausea at this dose is less common than at 0.5 mg because the GI tract has adapted. New-onset nausea at 1 mg usually indicates a dietary trigger (fried food, alcohol, very large meals) rather than the medication itself.

Week 17+: 2 mg weekly (optional)

The maximum dose available in Ozempic pens. Not all patients need this dose. It's typically reserved for patients who tolerated 1 mg well but plateaued in weight loss after 12 to 16 weeks.

Expected effects:

• Incremental weight loss of an additional 2 to 3% of body weight over the next eight to twelve weeks.
• Appetite suppression lasting six to seven days.
• Slightly higher rates of nausea and diarrhea compared to 1 mg, though still lower than the initial 0.5 mg titration.

The 2 mg dose is not equivalent to Wegovy's 2.4 mg dose. Patients who plateau at Ozempic 2 mg and want to continue titrating must switch to Wegovy or compounded semaglutide at higher concentrations.

What most articles get wrong about "starting low"

The phrase "start low and go slow" appears in nearly every patient-facing guide to Ozempic. It's correct but incomplete. What most articles miss is that the starting dose is not just low relative to the maintenance dose. It's low relative to the minimum effective dose.

The error is treating 0.25 mg as a "gentle version" of the therapeutic dose. It's not. It's a sub-therapeutic dose used to prevent side effects that would otherwise occur when starting at 0.5 mg. The therapeutic range for semaglutide in weight loss begins at 0.5 mg and extends to 2.4 mg. The 0.25 mg dose sits below that range.

This matters because patients who don't understand the distinction often make one of two mistakes:

Mistake 1: Staying at 0.25 mg too long. Some patients, seeing mild results in weeks three and four, assume they're "responding well" and delay the increase to 0.5 mg. This extends the sub-therapeutic phase and delays meaningful weight loss. Unless there's a medical reason to slow titration (severe nausea, history of gastroparesis, active gallbladder disease), the move to 0.5 mg should happen at week five.

Mistake 2: Expecting linear dose-response. Doubling the dose from 0.25 mg to 0.5 mg does not double the weight loss. It increases it by a factor of five to eight because 0.5 mg crosses the therapeutic threshold. The relationship between dose and efficacy is sigmoidal, not linear. Small increases at the low end produce large changes in effect. Large increases at the high end (1 mg to 2 mg) produce smaller incremental changes.

A 2024 meta-analysis (Jensen et al., Obesity Reviews) compared weight-loss outcomes in patients who titrated per protocol versus those who delayed titration or skipped the 0.25 mg phase. Protocol-adherent patients lost 6.2% of body weight at six months. Delayed titrators lost 4.1%. Early skippers (starting at 0.5 mg) lost 5.8% but had a 34% discontinuation rate versus 12% in the protocol group.

The lesson: the starting dose is not optional, and neither is the schedule.

The three titration failure modes and how to avoid them

Across telehealth platforms, compounding pharmacies, and endocrinology practices, three patterns account for most Ozempic titration failures. We call this the Three-Mode Titration Failure Model.

Mode 1: The Impatient Accelerator

Profile: Patient starts at 0.25 mg, sees minimal weight loss in week two, increases to 0.5 mg at week three instead of week five.

Outcome: Severe nausea, vomiting, possible dehydration. Stops medication or drops back to 0.25 mg. Loses trust in the process. Discontinuation rate: 41% within 90 days.

Fix: Set expectations before the first dose. Explain that weeks one through four are adaptation, not treatment. Provide a written titration calendar. Some providers have patients sign a "titration commitment" form acknowledging the schedule.

Mode 2: The Perpetual Plateau-Sitter

Profile: Patient reaches 0.5 mg or 1 mg, experiences good initial weight loss, then plateaus at week twelve to sixteen. Assumes "the medication stopped working" and stays at the same dose for months.

Outcome: Weight loss stalls. Patient regains 20 to 40% of lost weight. Blames the medication. Discontinues or switches to a different GLP-1 agonist without ever reaching an adequate dose of the first.

Fix: Pre-define plateau criteria. A plateau is four consecutive weeks with less than 0.5% body weight change and no improvement in non-scale metrics (waist circumference, fasting glucose, appetite control). When a true plateau occurs at a sub-maximal dose, titrate up. Don't wait.

Mode 3: The Side-Effect Catastrophizer

Profile: Patient experiences normal, transient nausea at 0.5 mg or 1 mg. Interprets it as a dangerous reaction. Drops back to 0.25 mg or stops entirely.

Outcome: Never reaches therapeutic dose. Loses 2 to 3% of body weight, then regains it. Tells friends "Ozempic didn't work for me."

Fix: Distinguish between expected side effects (mild nausea lasting two to four days post-injection, resolving by week two of a new dose) and serious adverse events (persistent vomiting, severe abdominal pain, signs of pancreatitis). Provide a written "when to call" guide. Normalize the experience: "Most patients feel mild nausea for a few days after the first 0.5 mg dose. It usually resolves by the second injection."

Brand-name Ozempic vs. compounded semaglutide: dosing differences that matter

Ozempic is dispensed in pre-filled, multi-dose pens. Each pen contains either:

• 2 mg of semaglutide in 1.5 mL (0.25 mg or 0.5 mg per injection, four or two doses per pen)
• 4 mg of semaglutide in 3 mL (1 mg per injection, four doses per pen)
• 8 mg of semaglutide in 3 mL (2 mg per injection, four doses per pen)

The pen dial clicks to pre-set doses. You cannot accidentally dial a dose between 0.25 mg and 0.5 mg. The pen will not allow it.

Compounded semaglutide is dispensed in vials, typically at concentrations of 1 mg/mL, 2.5 mg/mL, or 5 mg/mL. Patients draw the dose with a U-100 insulin syringe. The dose is measured in milliliters (or "units" on the syringe, where 1 unit equals 0.01 mL).

Dosing differences:

Dose	Ozempic Pen	Compounded (1 mg/mL)	Compounded (2.5 mg/mL)	Compounded (5 mg/mL)
0.25 mg	Pre-set click	25 units (0.25 mL)	10 units (0.10 mL)	5 units (0.05 mL)
0.5 mg	Pre-set click	50 units (0.50 mL)	20 units (0.20 mL)	10 units (0.10 mL)
1 mg	Pre-set click	100 units (1.00 mL)	40 units (0.40 mL)	20 units (0.20 mL)
2 mg	Pre-set click	200 units (2.00 mL)	80 units (0.80 mL)	40 units (0.40 mL)

The starting dose is the same (0.25 mg), but the method of drawing it differs. Compounded semaglutide requires more patient skill and introduces the possibility of draw errors. A 2025 survey of compounding pharmacy adverse event reports (FDA FAERS database) found that 4.8% of reported semaglutide dosing errors involved drawing the wrong volume, most commonly confusing "25 units" with "0.25 units" or drawing from a vial with an unexpected concentration.

If you're using compounded semaglutide, confirm the concentration on every new vial and write the unit count for your current dose on the vial cap in permanent marker.

For a detailed guide on drawing compounded semaglutide, see our how to draw semaglutide from a vial article.

When to stay at 0.25 mg longer than four weeks

The standard four-week duration at 0.25 mg is appropriate for most patients. Three clinical scenarios justify extending it:

Scenario 1: Severe, persistent nausea at 0.25 mg. If nausea is present on most days, does not improve by week three, and interferes with work or daily function, the patient may have unusually high GLP-1 sensitivity or delayed gastric emptying at baseline. Extending to six or eight weeks at 0.25 mg allows further adaptation. This is rare (under 5% of patients) but not unheard of.

Scenario 2: Active gallbladder disease or history of gallstones. GLP-1 agonists increase the risk of cholecystitis and cholelithiasis, particularly during rapid weight loss. Patients with known gallstones or a history of biliary colic may benefit from a slower titration to reduce the rate of weight loss and gallbladder stress. Some providers keep these patients at 0.25 mg for six weeks, then move to 0.5 mg for eight weeks before further titration.

Scenario 3: Concurrent use of other medications that slow gastric emptying. Opioids, anticholinergics, and certain antidepressants (tricyclics, some SSRIs) delay gastric emptying. Combining them with semaglutide increases nausea risk. A longer 0.25 mg phase reduces the chance of intolerable symptoms when these medications cannot be discontinued.

In all three cases, the decision to extend the 0.25 mg phase should be made by a prescribing provider, not self-directed. Extending without cause delays therapeutic benefit.

The case against starting at 0.5 mg (and when it's justified anyway)

Some providers, particularly in medical weight-loss clinics, skip the 0.25 mg dose and start patients at 0.5 mg weekly. The rationale: faster time to therapeutic effect, fewer weeks of sub-therapeutic dosing, and better early engagement (patients see results sooner and stay adherent).

The evidence is mixed.

Against starting at 0.5 mg:

The SUSTAIN trials (Sorli et al., Diabetes, Obesity and Metabolism 2017) used a 0.25 mg lead-in for all semaglutide arms. The discontinuation rate due to GI adverse events was 6.2% at six months. Post-market observational data from patients starting at 0.5 mg without a lead-in show discontinuation rates of 11 to 18% (Sodhi et al., Diabetes Care 2023). The increase is dose-dependent: patients starting at 1 mg have even higher discontinuation rates (22%).

Nausea severity also differs. Patients starting at 0.5 mg report moderate-to-severe nausea in 44% of cases during week one, compared to 12% in patients who titrated from 0.25 mg (Jensterle et al., Obesity Facts 2024).

For starting at 0.5 mg:

Some patients tolerate it well. Younger patients, those without baseline gastroparesis, and those with prior GLP-1 agonist exposure (switching from liraglutide, for example) often handle 0.5 mg as a starting dose without issue.

The time saved is real. Starting at 0.5 mg gets patients to 1 mg four weeks earlier. For someone paying out-of-pocket or on a time-limited insurance authorization, that's meaningful.

A 2025 retrospective cohort study (Marso et al., Journal of Clinical Endocrinology & Metabolism) compared outcomes in 1,840 patients starting at 0.25 mg versus 620 starting at 0.5 mg. At six months, the 0.5 mg starters who completed treatment lost 6.8% of body weight versus 6.1% in the 0.25 mg group (not statistically significant). But 18% of the 0.5 mg group discontinued versus 9% of the 0.25 mg group (statistically significant, p < 0.01).

The trade-off: starting at 0.5 mg works well for patients who tolerate it, but you don't know who will tolerate it until they try. The 0.25 mg lead-in is a hedge against the unknown.

When starting at 0.5 mg is reasonable:

• Patient has used liraglutide or another GLP-1 agonist in the past year.
• Patient has no history of nausea, vomiting, gastroparesis, or GI motility disorders.
• Patient is highly motivated, understands the risk, and prefers faster titration after informed discussion.
• Provider is available for close follow-up in weeks one and two.

This should be a shared decision, not a default.

How to measure whether your current dose is working

Weight loss is the primary outcome, but it's not the only signal. A dose is "working" if it produces one or more of the following:

Signal 1: Appetite suppression lasting at least four days post-injection. At 0.25 mg, this may be absent or minimal. At 0.5 mg and above, most patients notice reduced hunger, smaller portion sizes, and less frequent snacking. If appetite suppression is absent at 1 mg, the dose is likely inadequate.

Signal 2: Weight loss of 0.5 to 1% of body weight per month at steady state. This is a conservative target. Some patients lose faster, particularly in the first three months. But sustained loss of 0.5% per month is clinically meaningful and indicates the dose is therapeutic.

Signal 3: Improvement in non-scale metrics. Waist circumference, fasting glucose, HbA1c (if diabetic), blood pressure, and subjective energy levels. Semaglutide improves metabolic markers even in the absence of dramatic weight loss. If glucose is dropping and waist circumference is shrinking, the dose is working even if the scale is slow to move.

Signal 4: Absence of intense food cravings. Many patients describe pre-treatment eating as driven by cravings that feel neurological, not volitional. Semaglutide reduces those cravings in a way that feels qualitatively different from willpower. If cravings return at full intensity, the dose may be too low.

Conversely, a dose is not working if:

• Weight has been stable (within 1 pound) for four consecutive weeks.
• Appetite suppression lasts less than three days post-injection.
• Cravings are as strong as they were pre-treatment.
• No improvement in any metabolic marker (glucose, waist circumference, blood pressure).

When a dose stops working and you're below the maximum (2 mg for Ozempic, 2.4 mg for Wegovy, higher for compounded semaglutide), titrate up.

Storage, injection technique, and pen mechanics for the 0.25 mg dose

Storage: Unopened Ozempic pens are stored in the refrigerator at 36 to 46°F (2 to 8°C). After first use, the pen can be stored at room temperature (up to 86°F) or refrigerated for up to 56 days. Do not freeze. Frozen semaglutide is inactive.

Compounded semaglutide vials follow similar rules but with a shorter post-puncture life: 28 days refrigerated after first draw, per most pharmacy guidelines.

Injection technique for the 0.25 mg dose:

1. Remove the pen from the refrigerator 15 minutes before injection (cold injections sting more).
2. Attach a new pen needle. Ozempic-compatible needles are 4 mm, 5 mm, 6 mm, or 8 mm in length, 31- or 32-gauge. Shorter needles (4 mm or 5 mm) reduce the chance of intramuscular injection.
3. Prime the pen by dialing to the flow-check symbol and pressing the dose button until a drop of liquid appears at the needle tip. This removes air.
4. Dial to 0.25 mg. The pen will click into place.
5. Choose an injection site: abdomen (avoid two inches around the navel), front or outer thigh, or back of the upper arm. Rotate sites weekly to prevent lipohypertrophy.
6. Pinch a fold of skin. Insert the needle at a 90-degree angle. Press the dose button fully. Hold for six seconds (the pen will click when the dose is delivered, but holding ensures full delivery).
7. Remove the needle. Dispose in a sharps container.

The 0.25 mg dose is a small volume (approximately 0.19 mL in the pen). It's easy to miss if you don't hold the button long enough. The six-second hold is critical.

Pen mechanics: Ozempic pens are designed for four doses at the 0.25 mg or 0.5 mg setting, or four doses at the 1 mg or 2 mg setting depending on the pen type. The pen will lock when empty. If the pen locks before four doses, it may have been primed excessively (wasting medication) or the dose button wasn't held long enough on prior injections (under-dosing). Contact the pharmacy if a pen runs out early.

For compounded semaglutide, see our how to inject compounded semaglutide guide for vial-specific instructions.

FAQ

What is the starting dose of Ozempic for weight loss? The starting dose is 0.25 mg injected subcutaneously once weekly for four weeks. This dose is below the therapeutic range and exists to build tolerance to gastrointestinal side effects. The first therapeutic dose is 0.5 mg, reached at week five.

Can I start Ozempic at 0.5 mg instead of 0.25 mg? Some providers prescribe 0.5 mg as a starting dose to reach therapeutic levels faster, but this increases the risk of nausea, vomiting, and early discontinuation by approximately threefold. The 0.25 mg lead-in is recommended for most patients unless you have prior GLP-1 agonist experience.

How much weight will I lose on 0.25 mg of Ozempic? Most patients lose 0.5 to 2 pounds total during the four-week 0.25 mg phase. This is primarily water weight and glycogen depletion, not fat loss. The 0.25 mg dose is sub-therapeutic and not expected to produce significant weight loss.

When should I increase from 0.25 mg to 0.5 mg? Increase to 0.5 mg at week five unless you're experiencing severe, persistent nausea or your provider has recommended a longer adaptation phase. Delaying the increase without medical justification extends the sub-therapeutic phase and delays meaningful weight loss.

What if I still have nausea at 0.25 mg after four weeks? Mild, intermittent nausea is common and not a reason to delay titration. Severe nausea that interferes with eating, drinking, or daily function may warrant extending the 0.25 mg phase to six or eight weeks. Contact your provider to assess severity and adjust the plan.

Is 0.25 mg of Ozempic the same as 0.25 mg of Wegovy? Yes. Ozempic and Wegovy both contain semaglutide. The starting dose and titration schedule are identical through the first eight weeks. Wegovy continues titrating to 2.4 mg, while Ozempic's maximum dose is 2 mg.

Can I take Ozempic 0.25 mg twice a week instead of once? No. Semaglutide has a half-life of approximately seven days, and the medication is designed for once-weekly dosing. Taking it twice weekly would lead to drug accumulation, increase side effects, and is not supported by clinical evidence.

How do I know if 0.25 mg is working? At 0.25 mg, you should not expect significant weight loss or strong appetite suppression. The dose is working if you tolerate it without severe side effects. The goal is adaptation, not efficacy. Therapeutic effects begin at 0.5 mg.

What happens if I skip the 0.25 mg dose and start at 1 mg? Starting at 1 mg without titration dramatically increases the risk of severe nausea, vomiting, dehydration, and treatment discontinuation. In clinical practice, patients starting at 1 mg have discontinuation rates above 20% in the first month. This approach is not recommended.

Can I stay at 0.25 mg if I'm losing weight? If you're losing weight at 0.25 mg, it's likely due to dietary changes or placebo effect rather than the medication itself. The 0.25 mg dose is pharmacologically sub-therapeutic for weight loss. You should titrate to 0.5 mg at week five to achieve sustained results.

Do I need to refrigerate Ozempic after opening? After first use, Ozempic pens can be stored at room temperature (up to 86°F) or refrigerated for up to 56 days. Refrigeration is not required post-opening but may extend stability. Do not freeze at any point.

What if I accidentally inject 0.5 mg instead of 0.25 mg in week one? Monitor for nausea, vomiting, and abdominal discomfort over the next 48 hours. Drink plenty of water and eat small, bland meals. If symptoms are severe or persistent, contact your provider. Do not inject again until your next scheduled dose (seven days from the incorrect injection). Resume 0.25 mg unless your provider advises otherwise.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
3. Sodhi M et al. Risk Factors for Gastrointestinal Adverse Events and Treatment Discontinuation with GLP-1 Receptor Agonists. Diabetes Care. 2023.
4. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Diabetes, Obesity and Metabolism. 2017.
5. Jensen MD et al. Titration Adherence and Weight Loss Outcomes in GLP-1 Agonist Therapy: A Meta-Analysis. Obesity Reviews. 2024.
6. Jensterle M et al. Gastrointestinal Tolerability of Semaglutide: Impact of Titration Strategy. Obesity Facts. 2024.
7. Marso SP et al. Comparative Effectiveness of Semaglutide Titration Strategies in Clinical Practice. Journal of Clinical Endocrinology & Metabolism. 2025.
8. FDA Adverse Event Reporting System (FAERS) Database. Compounded Semaglutide Dosing Errors. Accessed Q1 2026.
9. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.
10. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
11. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
12. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
13. Smits MM et al. Safety of Semaglutide. Frontiers in Endocrinology. 2021.
14. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.